Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

CVS Health Seeks Return To LDL Treatment Targets To Control PCSK9s

This article was originally published in The Pink Sheet Daily

Executive Summary

Broad nature of latest cholesterol treatment guidelines makes it hard to deploy utilization management programs to control use of pricey new PCSK9 inhibitors, CVS Health argues in JAMA editorial.

Advertisement

Related Content

PCSK9 Coverage: Payers Wrestling With Proving Statin Intolerance
Praluent Coverage: Being First May Not Matter As Payers Await Repatha
Praluent Launch Brings Clinical Practice Challenges
Time, And Price, Are Right To Prescribe Statins To the Masses
Cholesterol Guidelines Look High And Low: Statin Market Extended At Both Ends

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register